AbbVie Aktie
WKN DE: A1J84E / ISIN: US00287Y1091
21.08.2025 14:52:57
|
AbbVie Reports Positive Topline Data From Phase 3 UP-AA Study Upadacitinib In Severe Alopecia Areata
(RTTNews) - AbbVie (ABBV) Thursday reported positive topline results from the second Phase 3 UP-AA study evaluating upadacitinib in adult and adolescent patients with severe alopecia areata (AA).
The study met its primary goal by achieving 80% or more scalp hair coverage in 45.2% and 55% of patients treated with upadacitinib 15 mg and 30 mg respectively.
These results were consistent with the previously announced topline results from the first study of Phase 3 UP-AA clinical program.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbbVie Incmehr Nachrichten
Analysen zu AbbVie Incmehr Analysen
Aktien in diesem Artikel
AbbVie Inc | 187,80 | 0,11% |
|